Interestingly, while ERBB2 is frequently amplified in various malignancies, including breast cancer, gastric cancer, or colon cancer [33,34,35], GBCs have a substantial rate of ERBB2 mutations [17,18,24]. This evidence concerns the gene ERBB2 and gastric cancer.